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Abstract
Background: Obesity is a risk factor for inadequate receipt of recommended preventive care services. The objective
of this study was to assess the relationship between increasing body mass index and receipt of influenza and
pneumococcal vaccinations. A systematic review of the PubMed, Embase, and Web of Science databases was
conducted from January 1966 to May 2015 for cohort and cross-sectional studies that assessed the relationship
between body mass index and the receipt of vaccinations for influenza and pneumococcus. Separate meta-analyses
by obesity classification were performed using a random effects model.
Results: Six cross-sectional and three cohort studies were included. Average vaccine uptake was 50.4 % for
influenza vaccination and 34.6 % for pneumococcal vaccination. Compared to normal weight patients, combined
odds ratio (95 % confidence interval) for influenza vaccination was 1.11 (95 % CI 0.97–1.25) for obese (≥30 kg/m2)
patients. When the outcome was reported by obesity class, combined odds ratios of influenza vaccination were
1.13 (95 % CI 1.02–1.24) for Class I (30–34.9 kg/m2) obesity, 1.21 (95 % CI 1.05–1.37) for Class II obesity (35–39.9 kg/
m2), and 1.19 (95 % CI 0.95–1.42) for Class III obesity (≥40 kg/m2) patients. Compared to normal weight patients,
combined odds ratio of pneumococcal vaccination were 1.20 (95 % CI 1.13–1.27) for obese patients. When the
outcome was reported by obesity class, combined odds ratios were 1.08 (95 % CI 1.04–1.13) for Class I obesity
patients, 1.13 (95 % CI 1.10–1.16) for Class II obesity patients, and 1.26 (95 % CI 1.15–1.38) for Class III obesity
patients for pneumococcal vaccination.
Conclusions: Combined findings from the current literature suggest that adults with obesity are more likely than non-
obese peers to receive vaccination for influenza and pneumococcus. However, suboptimal vaccination coverage was
observed across all body sizes, so future interventions should focus on improving vaccination rates for all adults.
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Background
The World Health Organization (WHO) Strategic Advis-
ory Group of Experts (SAGE) on Immunization and the
US Centers for Disease and Control and Prevention (CDC)
recommends vaccination of eligible adults for influenza
virus and streptococcus pneumoniae bacteria. Influenza
vaccination is recommended yearly for adults with few
contraindications [1–3]. For instance, pneumonia vaccin-
ation is recommended by the CDC for all persons over
65 years old, as well as for younger adults with select
medical risk factors (e.g. diabetes mellitus, chronic heart
disease, chronic lung disease, chronic liver disease, chronic
renal disease, cancer, HIV infection, etc) [4]. Influenza vac-
cination decreases the rate of diagnosed influenza and the
severity of influenza morbidity and mortality, particularly
in persons with comorbid diseases [5–7]. Similarly, vaccin-
ation against streptococcus pneumoniae bacteria effectively
prevents laboratory-confirmed pneumonia infections and
invasive pneumococcal disease [8–10].
Despite the many benefits of vaccination and their strong
endorsement from major national professional organiza-
tions, vaccine uptake is lower than desired. For example, in
the US, the median vaccination rate is 60.7 % for influenza
and 70.0 % for pneumococcal vaccination among adults in
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2011, compared to US Healthy People 2020 goals for influ-
enza (70 %) and pneumococcal (90 %) vaccination of eli-
gible adults [8, 9]. Many factors are known to affect the
receipt of vaccination, including age, race, personal beliefs,
and comorbid conditions [10–12]. Persons with chronic ill-
nesses suffer disproportionate morbidity and mortality
from vaccine-preventable illness; therefore, there is particu-
lar interest in ensuring vaccine coverage of these especially
vulnerable adults.
As with many other chronic diseases, obesity is associ-
ated with increased mortality from both influenza and
pneumococcal infections [13–15]. Obesity – which affects
approximately one third of US adults and 600 million
people worldwide – may impact a person’s receipt of pre-
ventive health services, but the direction of this association
is unclear [16, 17]. In the case of cancer screening, increas-
ing levels of obesity in women are associated with lower
rates of breast and cervical cancer screening [18, 19]. How-
ever, studies in Medicare and Veteran’s Administration
populations have documented higher rates of vaccination
in obese patients [20] The purpose of this systematic re-
view and meta-analysis is to determine whether increasing
body mass index is associated with less likelihood of adults
receiving indicated influenza and pneumococcal vaccina-
tions in cohort and cross-sectional studies.
Methods
Search strategy and selection criteria
We adhered to the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA) and Guidelines
for Meta-Analyses and Systematic Reviews of Observa-
tional Studies (Additional file 1) recommendations in con-
ducting this systematic review. The study was deemed
exempt from review by the University of Michigan Institu-
tional Research Board – Medical. PubMed (January 1966
to May 2015), EMBASE (January 1980 to May 2015), and
Web of Science (January 1900 to May 2015) databases
were searched using the preassigned search terms. We
reviewed the cited references of the included studies for
additional studies. Reviewers included studies that com-
pared vaccination rates for influenza and pneumococcus
by patient obesity where the predictor of interest was pa-
tient body mass index, and the outcome of interest was in-
fluenza or pneumococcal vaccination.
We developed a detailed search protocol with the help
of a medical librarian. Full details of the search strategies
are noted in the Appendix 1. In brief, our search included
controlled vocabulary and keywords similar to “obesity”
and “streptococcus pneumococcal or influenza virus vac-
cination,” and the outcome “receipt of vaccination”. We
included prospective or retrospective cross-sectional or
longitudinal cohort studies. Only articles published in
English were included. The search and review was last up-
dated in May 2015. The study protocol was not eligible
for registration with PROSPERO International prospective
register of systematic reviews due to the outcome being
process-related rather than intervention-related [21].
Study selection
All article titles and abstracts were reviewed for inclu-
sion by two independent reviewers (BI, RP, or JH) using
a template defining inclusion and exclusion criteria.
The inclusion criteria for the first screening were: a
population including comparison of non-obese and
obese adults, the receipt of vaccination for influenza or
pneumococcus as a recorded outcome and identifica-
tion as a cohort or cross-sectional study. The inclusion
criteria for the full-text, second screening used the
same inclusion criteria as the first. Discrepancies in any
of the reviews were adjudicated by consensus.
Data extraction and quality assessment
The same two independent reviewers examined the full
text of the study, assessing for the protocol inclusion and
exclusion criteria. Human papilloma virus was included in
the search terms, but no studies met inclusion criteria; we
are therefore unable to include this vaccine in the analysis.
The study team reviewed all studies meeting criteria for
relevant information and results were extracted using a
data collection template. Abstracted data included de-
tailed information about the study objectives, design,
participants, covariates, outcomes, statistical methods,
and a quality assessment.
We assessed methodological quality using the US
National Institute of Health National Heart, Lung, and
Blood Institute Quality Assessment Tool for Observa-
tional Cohort and Cross-Sectional Studies [22]. This tool
measures 14 different criteria which are then used to give
each study an overall quality rating of good, fair, or poor.
Data synthesis and statistical analysis
We created tables to summarize the study populations, in-
clusion and exclusion criteria, vaccination type, and out-
comes. The principal summary measure was odds ratios.
We performed a meta-analysis in studies that reported
body mass index in the categories defined by the World
Health Organization and the National Institutes of Health
(normal: body mass index (BMI) 18.5–24.9 kg/m2, obesity
BMI ≥ 30 kg/m2, class I obesity BMI 30–34.9 kg/m2, Class
II obesity BMI 35–39.9 kg/m2, Class III obesity BMI
>40 kg/m2) or between normal weight and obesity
≥30 kg/m2 if that was the only comparison reported.
We used random-effects (DerSimonian and Laird)
models to calculate odds ratios and 95 % confidence inter-
vals for pneumococcal and influenza vaccination [23]. For
studies reporting adjusted relative risk or predicted preva-
lence, we calculated odds ratios with normal body mass
index as the reference category. We calculated an I2 statistic
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to test for heterogeneity, and the Begg’s test and visual in-
spection of the funnel plot to assess for the possibility of
publication. We used STATA 13.0 (StataCorp, College Sta-
tion, TX) for all analyses. The study was deemed exempt by
The University of Michigan Medical Institutional Review
Board (HUM00097519).
Results
Of 342 titles identified in the full search of three data-
bases and hand searching, nine articles met inclusion
criteria (Fig. 1).
Obesity classifications
Among included studies, obesity was most frequently
measured by BMI, which was most often defined as
underweight (BMI < 18.5 kg/m2), healthy weight (BMI
18.5–24.9 kg/m2), overweight (BMI 25–29.9 kg/m2),
obese (BMI ≥30 kg/m2) [20, 24–27] or defined by World
Health Organization cutoff points as underweight (BMI
< 18.5 mg/m2), healthy weight (BMI 18.5–24.9 kg/m2),
overweight (BMI 25–29.9 kg/m2), obesity Class I (BMI
30–34.9), obesity Class II (BMI 35–39.9 kg/m2), obesity
Class III (BMI ≥40 kg/m2) [28–32]. A single study de-
fined obesity as a BMI ≥30 kg/m2 or waist circumference
>102 cm in men and >88 cm in women [26]. The refer-
ence population for comparison was generally the nor-
mal weight category; in one case overweight and normal
weight and underweight were grouped together and used
as the reference category [33].
Outcome definitions
Influenza vaccination was defined most often as receiving
vaccination within the past 12 months or past year. Single
studies defined influenza vaccination as receipt within the
past 2 years or 4 out of the past 5 years (and at least
8 months apart) [31, 32]. Pneumococcal vaccination was
Fig. 1 Study flow diagram
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defined most often as receiving vaccination at least once in
the participant’s life. A single study defined pneumococcal
vaccination as receipt within the past 5 years [25].
Study characteristics
Study populations involved one of two groups: 1) adults
aged 18 or older (commonly for influenza vaccination
studies) and 2 adults aged 65 years or older (commonly
for pneumococcal vaccination studies). All studies exam-
ined both men and women in population-based (between
3000 and 1 million participants) national or international
settings. Six studies were cross-sectional, three were co-
hort studies, and all studies included data for was from
population-based surveys, including the Behavioral Risk
Factor Surveillance System, Medical Expenditure Panel
Survey, Health and Retirement Study, Medicare Current
Beneficiary Survey, and the Survey of Health, Aging, and
Retirement in Europe. BMI and vaccination information
was generally self-reported except for studies using Vet-
eran’s Health Administration (VA) populations, where
these data represent measure biometric indices and vac-
cination variables abstracted from the electronic medical
record [20, 32].
Quality assessment
Using the United States National Institute of Health
(NIH) National Heart, Lung and Blood Institute (NHLBI)
Quality Assessment Tool for Observational Cohort and
Cross-Sectional Studies, we rated 4 studies at a “good”
quality rating and 5 studies at a “fair” quality rating. The
studies all used well-designed surveys except studies using
VA or Medicare administrative datasets. The number and
type of covariates differed widely among the studies; use
of a more complete list of model covariates was a key dif-
ferentiating characteristic of studies rated “good”.
Confounder covariates
Most studies included a wide variety of covariates in their
regression models. Common covariates included age, sex,
race, ethnicity, education level, tobacco and drug use.
Measures of prior healthcare utilization were included in
five studies [20, 24, 27, 30, 31]. Utilization measures varied
from time since last routine check-up to ever having re-
ceived a mammogram to number of ambulatory visits in
the past year.
Study outcomes
The full study characteristics are presented in Table 1.
The general vaccination rate for influenza ranged from
21.1 % [32] to 72.2 % [31]; the average vaccine uptake was
50.4 %. The general vaccination rate for pneumococcus
ranged from 13.4 % [25] to 49.5 % [20]; the average
vaccine uptake was 34.6 %. Of nine studies, three studies
reported a statistically significant association between
increasing BMI and receipt of vaccination [20, 30, 32],
four studies were unable to reject the null hypothesis that
there was no association between increasing BMI and re-
ceipt of vaccination [24–27], and two studies reported a
statistically significant inverse association between in-
creasing BMI and receipt of vaccination [31, 33]. Com-
pared to normal weight patients, the combined odds ratio
for influenza vaccination was 1.11 (95 % CI 0.97–1.25) for
obese (≥30 kg/m2) patients (Fig. 2) . When the outcome
was reported by obesity class, combined odds ratios were,
1.13 (95 % CI 1.02–1.24) for class I obesity patients, 1.21
(95 % CI 1.05–1.37) for class II obesity patients, and 1.19
(95 % CI 0.95–1.42) for class III obesity patients for influ-
enza vaccination (Figs 3, 4 and 5).
Among the three studies with NIH NHLBI Quality As-
sessment Tool “good” ratings, where model covariates
included measures of outpatient utilization, one study
each that found a positive or negative association, and
two studies found a statistically insignificant association
between receipt of vaccination and increasing body mass
index [20, 24, 27, 31].
Among studies that measured pneumococcal vaccin-
ation, three of four studies noted a positive association be-
tween receipt of vaccination and increasing body mass
index [20, 30, 32]. Compared to normal weight patients,
the combined odds ratio for pneumococcal vaccination
was 1.20 (95 % CI 1.13–1.27) for obese patients. When the
outcome was reported by obesity class, combined odds ra-
tios were 1.08 (95 % CI 1.04–1.13) for class I obesity pa-
tients, 1.13 (95 % CI 1.10–1.16) for class II obesity
patients, and 1.26 (95 % CI 1.15–1.38) for class III obesity
patients for pneumococcal vaccination (Figs. 2, 3 and 4).
Visual inspection of the funnel plots did not suggest
publication bias, but in many of the comparisons there
were few studies to compare. Begg’s test for publication
bias was insignificant except for pneumococcal vaccin-
ation and Class I and III obesity (P = 0.04 and P = 0.04)
(Appendix 2).
Discussion
This systematic review and meta-analysis identified nine
studies evaluating the association between patient body
mass index and receipt of influenza and pneumococcal
vaccination. It suggests that patients with obesity overall
are more likely than patients without obesity to receive
vaccination for both influenza and pneumococcus.
A variety of patient-level and systems-level factors may
explain this finding. Patient level factors such as perceived
susceptibility to disease and perceived vaccine effective-
ness are predictors of vaccine acceptance [34, 35]. Adults
with obesity may be more likely to perceive higher risk
from vaccine-preventable diseases and more accepting of
the benefits and safety of recommended vaccinations. As
patients with obesity are frequently counseled about the
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Table 1 Results for studies included in qualitative and quantitative analysis




Banerjea et al. [24] 2008 Influenza vaccination in last year 4299 Age, race/ethnicity, marital status, education,
employment, income, access to health care,
contact with healthcare system, medical
conditions, health status, comorbid chronic
conditions, mental illness
55.6 % Good







Age, sex, race/ethnicity, marital status, education,
income, self-rated health, quartile of clinical com-
plexity, quartile of visit frequency, year of receipt,
age squared term, interaction between weight




Hoeck et al. [25] 2014 Influenza vaccination in past year; Pneumo-
coccal vaccination within last 5 years
4544 Age, gender, highest level of education, living
situation, region, self-assessed health, longstanding





Leon-Munoz et al. [26] 2005 Influenza vaccination in last 1 year 2919 Age, educational level, size of place of residence,
tobacco, alcohol
62.8 % Fair





Age, education, race/ethnicity, self-reported per-





Ostbye et al. [31] 2005 Influenza vaccination in the last 2 years 10588 Age, gender, race, education, birth country, marital
status, household income, insurance, smoking,
exercise, self-reported health, diabetes, heart dis-
ease, cognitive impairment, hospitalization in last




2007 Influenza vaccination in last year 13859 Age, gender, marital status, years of education,
purchasing power parity-household income ad-
justed for size of household, smoking status, ex-
cessive alcohol consumption, country of residence,
diagnosis of hypertension, heart disease, diabetes,
cholesterol, arthritis, reported number of ambula-
tory visits
50.9 % Good
Stehr-Green et al. [33] 1990 Influenza vaccination in last year 9799 Gender, race, education, income, employment
outside home, seat belt use, smoking, smokeless
tobacco, alcohol use, drinking and driving,
sedentary lifestyle, medical exam in last year,
hypertension, ever had mammogram
32 % Fair
Yancy et al. [32] 2010 Influenza vaccination 4 out of 5 most recent
years, at least 8 mo apart for 65+ or high risk;
Pneumo-coccal vaccination once for 65 years
old or older or high-risk under 65 year olds
1058599 Age, gender, race/ethnicity, marital status, outside
insurance, healthcare eligibility, geographic region,
primary care provider provider, health status

















risks of obesity-related disease, these patients may per-
ceive a higher personal risk of future disease than non-
obese patients.
Even as this study finds that increasing body mass index
was associated with increasing rates of vaccination for in-
fluenza and pneumococcus, the overall rate of vaccination
observed is still very low. Only half of the included studies
reported vaccine uptake greater than 50 %. Large percent-
ages of all adults, both obese and non-obese are still
under-vaccinated, so there is still much progress to be
made in people of all body sizes to reach these reasonable
vaccination uptake goals [9].
The study populations in this systematic review vary sig-
nificantly by age, sex, and race. Some studies include only
older adults, due to the age-related recommendations for
pneumococcal vaccination, while others include the full
general adult populations. The effect of comorbid illness
like obesity may interact with age to affect the receipt of
preventive services like vaccinations. Analogous studies in
cancer screening have noted decreased rates of screening
as age increases, but not as comorbidities increase [36–38].
Unlike non-obese populations, as obese patient’s age, they
may be more likely to be identified for preventive health
services. For instance, obesity and diabetes are closely
Fig. 2 Meta-analysis of studies on receipt of influenza and pneumococcal vaccination with body mass index categorized by normal weight and
obese (≥30 kg/m2)
Fig. 3 Meta-analysis of studies on receipt of influenza and pneumococcal vaccination with body mass index categorized by Normal Weight and
Class I Obesity (30–34.9 kg/m2)
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associated, and diabetes is an indication for vaccination
for both influenza and pneumococcus. This may explain
why older obese adults included in this analysis were more
likely than non-obese peers to receive pneumococcal vac-
cination. In addition, sex, race, and ethnicity are all associ-
ated with variations in the utilization of preventive care
services like colorectal cancer screening [39, 40]. Age, sex,
and race differences within the included studies may ex-
plain some of the variation in effect size an effect direc-
tionality noted in the meta-analysis.
Systematic reviews and meta-analyses of breast, cer-
vical and colon cancer screening document variation in
the relationship between obesity and cancer screening,
but overall suggest a small but persistent inverse rela-
tionship between increasing BMI and decreasing cancer
screening uptake [18, 19, 41, 42]. The current study’s
findings may be different due to the complex and mul-
tiple factors that influence uptake of preventive services
in persons with obesity.
The current study’s converse finding that obesity is asso-
ciated with increased vaccination may reflect the complex
factors that affect the receipt of preventive care services in
patients with obesity. Vaccination is a very different type of
preventive care service than cancer screening. Vaccination
Fig. 4 Meta-analysis of studies on receipt of influenza and pneumococcal vaccination with body mass index categorized by Normal Weight and
Class II Obesity (35–39.9 kg/m2)
Fig. 5 Meta-analysis of studies on receipt of influenza and pneumococcal vaccination with body mass index categorized by Normal Weight and
Class III Obesity (≥40 kg/m2)
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is a relatively simple procedure that may be performed dur-
ing almost any outpatient or inpatient interaction. Patients
stay fully dressed, and the procedure may be performed by
nursing personnel with minimal physician oversight. Can-
cer screening for breast and cervical cancer are presently
much more invasive and complex procedures. Patients
with obesity have reported multiple barriers to cancer
screening including provider stigma, personal discomfort
with the procedures, and perceived disrespectful commu-
nications with healthcare providers and staff [41, 43, 44].
Finally, cancer screening is more subject to issues of over-
use which may complicate the interpretation of studies on
the receipt of cancer screening; overuse of vaccination ser-
vices is rarely a concern, which simplifies interpretation of
studies on the receipt of vaccination services.
This study, together with previous findings in cancer
screening, suggests that patient body mass index should be
examined as a part of any evaluation of the receipt of pri-
mary preventive services. Whether obesity is a risk factor
for underuse, as in cancer screening, or for overuse, as in
influenza and pneumococcal vaccination, both trends are a
potential problem for health care delivery systems. These
preventive care inefficiencies experienced by patients with
obesity may be addressed through health policy or system
interventions. For instance, electronic medical record re-
minder systems may be able to use recorded body mass
index to remind providers to perform cancer screening for
patients with obesity or to remind providers to offer indi-
cated immunizations for patients that are only present to
the healthcare system occasionally. Or health care payers
could incentivize providing immunization by improving re-
imbursement for these services. Finally, continued research
should examine how to increase uptake and efficiency of
vaccination among all people, especially in groups prone to
healthcare disparities, including patients with obesity.
While our search criteria also included immunization
for human papilloma virus, there were no studies eligible
by our criteria. While this immunization has only been
available within the last 10 years and so has been studied
less than influenza and pneumococcal vaccination, future
studies should consider whether receipt of immunization
is affected by patient obesity as has been shown in other
immunization and cancer screening interventions.
Our findings should be interpreted within the limitations
of our study design. The studies identified in our system-
atic review and meta-analysis demonstrates significant het-
erogeneity in the direction and effect size of the association
between obesity and receipt of influenza and pneumococ-
cal vaccination. The index of heterogeneity in this the
meta-analysis ranges from 0 % (no heterogeneity between
studies) to 96.4 % (high heterogeneity between studies) de-
pending on the vaccination type and obesity comparison.
The wide confidence intervals observed in our meta-
analysis are attributable to effect size variations in the
included studies. Varied study designs (high quality cross-
sectional survey vs. administrative record studies), and
differences in sample selection, measurement of vaccine
receipt, and adjustment for possible confounding explains
much of heterogeneity in effect direction as well as the
broad confidence intervals noted in this meta-analysis.
In addition to heterogeneity in study populations, the
included studies’ models vary significantly in the selection
of covariates used to control for confounding. Beyond the
importance of age, sex, and race for reasons noted above,
controlling for health care utilization is important. Three of
the nine studies controlled for medical care utilization (in
either number of outpatient visits and/or hospitalizations in
the past year). Increasing body mass index is associated
with increased utilization of medical services [45, 46]. In-
creasing interactions with the healthcare system likely in-
crease the chance of receiving preventive care services like
vaccinations over time. By controlling for utilization, the
results of the study better describe the odds of receipt of
vaccination services during a single visit, rather than during
a time interval such as the last 12 months, which is the out-
come of interest in many of these studies. However, in the
ideal situation where the patient receives the indicated
vaccination at the first visit, controlling for all visits after
this one dilutes the effect of the appropriate intervention
because the outcome is controlled for total amount of
utilization, not just utilization before vaccination.
Conclusion
In summary, the receipt of vaccination for pneumococcus
and influenza is an important health care quality indicator.
While obese patients are associated with higher levels of
vaccination, the overall levels of vaccination are low in all
populations. Our findings highlight the importance of con-
tinued efforts to improve patient access to and utilization
of recommended adult vaccinations. Persons with comor-
bidities like obesity are particularly vulnerable to morbidity
from vaccine-preventable illnesses, and future research is
needed to better identify patient-level and systems-level
predictors of vaccine uptake in this group.
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Appendix 1
Table 2 Full search vocabulary and search results
Population
PubMed MeSH
(“anthropometry”[MeSH Terms] OR “body mass index”[MeSH Terms] OR “body weight”[MeSH Terms] OR “overweight”[MeSH Terms] OR
“obesity”[MeSH Terms] OR “risk factors”[MeSH Major Topic] OR “life style”[MeSH Major Topic] OR “adiposity”[MeSH Terms])
PubMed Keywords
(“body mass index” [tiab] OR “body weight” [tiab] OR “body mass” [tiab] OR “overweight” [tiab] OR “body fat” [tiab] OR “obesity” [tiab] OR “obese”
[tiab] OR “heavy” [tiab] OR “risk factors” [tiab] OR “adiposity” [tiab] OR “body mass” [tiab])
EMBASE
Emtree
‘anthropometric parameters’/exp OR ‘body mass’/exp OR ‘obesity’/exp OR ‘adiposity’/exp OR ‘overweight’/exp
Keywords
OR obesity OR body mass OR overweight OR obese OR risk factor OR adiposity
Intervention
PubMed MeSH
“Immunization”[Mesh]OR “Vaccines”[Mesh] OR “Pneumococcal Infections”[Mesh] OR “Pneumococcal Vaccines”[Mesh] OR “Influenza Vaccines”[Mesh]
OR “Influenza, Human/prevention and control”[Mesh] OR”Papillomavirus Vaccines”[Mesh] OR “Human papillomavirus 6”[Mesh] OR “Human
papillomavirus 11”[Mesh] OR “Human papillomavirus 18”[Mesh] OR “Human papillomavirus 16”[Mesh] OR “Human papillomavirus 6”[Mesh]
PubMed Keywords
(“Immunization” [tiab] OR “Vaccination” [tiab] OR “Vaccine” [tiab] OR “pneumococcal vaccine” [tiab] OR “pneumonia vaccine” [tiab] OR
“pneumococcal immunization” [tiab] OR “pneumonia immunization” [tiab]OR “influenza vaccine” [tiab] OR “influenza immunization” [tiab] OR
“flu vaccine” [tiab] OR “HPV vaccine” [tiab] OR “human papillomavirus virus vaccine” [tiab] OR “HPV immunization” [tiab] OR “human
papillomavirus virus immunization” [tiab] OR “Gardasil” [tiab] OR “Silgard” [tiab] OR “Cervarix” [tiab])
EMBASE
Emtree
‘immunization’/exp OR ‘pneumococcal infection’/exp OR ‘influenza’/exp OR ‘papilloma virus’/exp
Keywords
(Immunization OR Vaccination OR Vaccine OR pneumococcal vaccine OR pneumonia vaccine OR pneumococcal immunization OR pneumonia
immunization OR influenza vaccine OR influenza immunization OR flu vaccine OR HPV vaccine OR human papillomavirus virus vaccine OR HPV
immunization OR human papillomavirus virus immunization OR Gardasil OR Silgard)
Outcome
PubMed MeSH
(“Diagnostic Errors”[MeSH Terms]) OR
PubMed Keywords
“screening rate” [tiab] OR “immunization rate” [tiab] OR “vaccination rate” [tiab] OR “repeat screening” [tiab] OR “quality of care” [tiab] OR
“preventive services” [tiab] OR “preventive care” [tiab] OR “medical utilization” [tiab] OR “receipt of screening” [tiab]
EMBASE
Emtree
‘diagnostic error’/exp OR ‘preventive health service’/exp OR ‘health care utilization’/exp
Keywords
‘screening rate’ OR ‘immunization rate’ OR ‘vaccination rate’ OR ‘repeat screening’ OR ‘quality of care’ OR ‘preventive services’ OR ‘preventive
care’ OR ‘medical utilization’ OR ‘receipt of screening’
Web of Science:
Population, Intervention and Outcome
TS = ((‘body mass’[TS] OR ‘obesity’ OR ‘overweight’ OR ‘obese’ OR ‘adiposity’) AND (Immunization OR Vaccination OR Vaccine OR pneumococcal
vaccine OR pneumonia vaccine OR pneumococcal immunization OR pneumonia immunization OR influenza vaccine OR influenza immunization
OR flu vaccine OR HPV vaccine OR human papillomavirus virus vaccine OR HPV immunization OR human papillomavirus virus immunization OR
Gardasil OR Silgard) AND (screening rate OR immunization rate OR vaccination rate OR repeat screening OR quality of care OR preventive
services OR preventive care OR medical utilization OR receipt of screening))
Refined by: DOCUMENT TYPES: (PROCEEDINGS PAPER)
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
Results of Search:
PubMed
Population = 1071513 10/28/2014
Intervention = 343246 10/28/2014
Outcome = 125015 10/28/2014
Population + Intervention + Outcome =134 10/28/2014
Population = 1115328 5/29/2015
Intervention = 352483 5/29/2015
Outcome = 128816 5/29/2015
Population + Intervention + Outcome =145 5/29/2015
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Additional file 1: PRISMA 2009 Checklist. (DOCX 29 kb)
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